Chief Regulatory Officer · Acumen Pharmaceuticals, Inc. · Common Stock
Open-market sale
$2K reported value · 12.5% of prior position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
1 other actor traded the same direction within 14 days
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 26 | Doherty James J.President and CDO |  ABOSAcumen Pharmaceuticals, Inc.Open-market sale | SELL | $3,379 1,700 sh | Jan 9, 2026 traded Jan 7, 2026 | |
| 26 | Doherty James J.President and CDO | ABOSAcumen Pharmaceuticals, Inc. Open-market sale | SELL | $12K 6,467 sh | Jan 9, 2026 traded Jan 8, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $2,176
Schacterle Amy filed this Form 4 reporting a open-market sale of ABOS on Jan 7, 2026. It became public on Jan 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.
Price history for ABOS is unavailable.
An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.